Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.26 +1.1%	$2.97	$1.05 ▼ $3.97	$366.19M	1.92	593,223 shs	450,990 shs
GHRS GH Research	$13.82 +1.4%	$13.95	$6.00 ▼ $20.50	$719.32M	0.98	333,306 shs	39,537 shs
INCR InterCure	$1.62 -0.7%	$1.55	$1.17 ▼ $2.30	N/A	1.18	22,389 shs	36,326 shs
LVTX LAVA Therapeutics	$1.56 +0.3%	$1.43	$0.85 ▼ $2.09	$40.91M	0.5	204,052 shs	110,852 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.74%	+3.86%	+3.20%	+15.55%	+5.39%
GHRS GH Research	+1.79%	+6.65%	-9.01%	+12.83%	+20.41%
INCR InterCure	-0.31%	0.00%	+7.95%	+4.15%	-23.47%
LVTX LAVA Therapeutics	+1.97%	+1.64%	+1.97%	+17.34%	-16.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.3629 of 5 stars	3.5	1.0	0.6	0.8	0.6
GHRS GH Research	2.2898 of 5 stars	3.4	3.0	1.6	2.5	0.0
INCR InterCure	0.8118 of 5 stars	0.0	3.0	3.8	0.0	0.6
LVTX LAVA Therapeutics	2.0898 of 5 stars	3.0	5.0	2.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	138.10% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	131.63% Upside
INCR InterCure	0.00	N/A	N/A	N/A
LVTX LAVA Therapeutics	2.00	Hold	$2.69	72.67% Upside

Current Analyst Ratings Breakdown

Latest ADCT, GHRS, INCR, and LVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	5.17	N/A	N/A	($1.77) per share	-1.84
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
INCR InterCure	$64.55M	N/A	N/A	N/A	$2.36 per share	N/A
LVTX LAVA Therapeutics	$11.98M	3.42	N/A	N/A	$0.76 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.57	N/A	N/A	N/A	-220.00%	N/A	-53.73%	11/6/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.05	N/A	N/A	N/A	N/A	-106.29%	-38.24%	N/A

Latest ADCT, GHRS, INCR, and LVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A
8/12/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	-$0.50	-$0.14	-$0.50	$17.82 million	$18.84 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.93	4.66
GHRS GH Research	N/A	29.49	29.49
INCR InterCure	0.34	1.73	1.18
LVTX LAVA Therapeutics	N/A	10.78	10.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
GHRS GH Research	56.90%
INCR InterCure	8.34%
LVTX LAVA Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
GHRS GH Research	41.60%
INCR InterCure	0.24%
LVTX LAVA Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	112.50 million	106.42 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
INCR InterCure	350	N/A	N/A	Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable

ADCT, GHRS, INCR, and LVTX Headlines

Recent News About These Companies

LAVA Therapeutics N.V. (LVTX) - Yahoo Finance

August 20, 2025 | finance.yahoo.com

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

August 8, 2025 | prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

August 7, 2025 | prnewswire.com

Jefferies Downgrades LAVA Therapeutics N.V. (LVTX)

August 5, 2025 | msn.com

LAVA Therapeutics Shares Climb on Buyout Deal with XOMA Royalty

August 4, 2025 | msn.com

XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics

August 4, 2025 | msn.com

LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

August 4, 2025 | businesswire.com

LAVA Therapeutics Shareholders Approve Key Proposals in Meeting

June 13, 2025 | tipranks.com

Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation

May 16, 2025 | finance.yahoo.com

LAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 15, 2025 | finanznachrichten.de

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

May 14, 2025 | globenewswire.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock News

April 16, 2025 | gurufocus.com

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency

April 16, 2025 | quiverquant.comQ

LAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...

April 16, 2025 | gurufocus.com

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

April 16, 2025 | globenewswire.com

Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year

March 29, 2025 | markets.businessinsider.com

LAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99M

March 28, 2025 | seekingalpha.com

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

March 28, 2025 | globenewswire.com

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

February 28, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ADCT, GHRS, INCR, and LVTX Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.26 +0.04 (+1.09%)

As of 02:17 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

GH Research NASDAQ:GHRS

$13.82 +0.19 (+1.36%)

As of 02:16 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

InterCure NASDAQ:INCR

$1.62 -0.01 (-0.67%)

As of 02:17 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

LAVA Therapeutics NASDAQ:LVTX

$1.56 +0.01 (+0.32%)

As of 02:00 PM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time